Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call reveals strong financial improvements, such as a significant net loss reduction and increased EPS. AI product traction and efficiency benefits are well-received, with positive market positioning and growth in key segments. Despite some challenges in transactional revenues, the company's strategic shift towards subscription models and AI integration promises future growth. The Q&A section reinforces management's confidence and provides clarity on competitive positioning and market opportunities, particularly in China. Given the company's market cap, these factors suggest a positive stock price reaction in the near term.

Key Financial Performance

Revenue $586 million, supported by continued VCP progress and execution across the portfolio. Organic ACV growth was 1.6% with subscription organic revenue growth of 1.7%, reflecting increased adoption of subscription-based solutions.

Adjusted EBITDA $241 million, representing a 41% margin, up almost 200 basis points year-over-year, highlighting the benefit of the subscription-first strategy and disciplined cost management.

Free Cash Flow Approximately $79 million, which allowed the company to retire $143 million of debt during the quarter.

Net Loss $40 million, a $64 million improvement over the prior year, driven by a foreign exchange benefit as well as lower restructuring, income tax, and interest expenses.

Adjusted Diluted EPS $0.18, up nearly 30% or $0.04 over the prior year, attributed to adjusted EBITDA growth, lower interest expense, lower tax expense, and a lower share count due to last year's repurchases.

Operating Cash Flow $135 million, driven by higher working capital due to incentive compensation payments, partially offset by higher adjusted EBITDA.

Organic Revenue Growth Nearly 2% for subscription growth, partially offset by lower recurring and transactional revenues.

Renewal Rates (Intellectual Property) Improved approximately 100 basis points, helping organic ACV trends improve to nearly flat, indicating progress in subscription and renewal discipline.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

ProQuest subscription solution: Strong adoption with over 600 new subscriptions sold in the last 12 months, reinforcing revenue durability and predictability.

DRG Fusion: Won a new Top 20 global pharmaceutical customer for this real-world data analytics platform, showcasing its value proposition.

OFF-X: Secured a six-figure subscription win with a biotech company for this preclinical and clinical safety intelligence platform.

Brand image search: Released advanced AI capabilities, including clustering and multilingual support, enhancing global IP professionals' decision-making.

China market expansion: Secured a multiproduct institutional deal with Fuyao University, a new research-oriented university in China, demonstrating ability to deliver integrated solutions.

AI integration: Leveraging AI across sales, customer care, software engineering, and corporate functions to drive efficiency, reduce manual effort, and improve accuracy.

Cost management: Disciplined cost management led to a 200 basis point adjusted EBITDA margin expansion year-over-year.

Debt reduction: Retired $143 million of debt during the quarter, contributing to financial stability.

Value Creation Plan: Focused on business model optimization, improved sales execution, accelerated AI innovation, and portfolio rationalization to unlock long-term shareholder value.

Life Science & Healthcare business divestiture: Actively pursuing the sale of this segment to concentrate on high-return areas and maximize shareholder value.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Market Conditions: Potential risks from economic uncertainties and foreign exchange fluctuations, which could impact revenue and profit margins.

Regulatory Hurdles: Introduction of new corporate tax in Jersey, increasing cash tax expenses by $5 million to $10 million.

Strategic Execution Risks: Ongoing process of selling the Life Science & Healthcare business, with no guarantee of outcome, which could impact strategic focus and financial guidance.

Supply Chain Disruptions: No explicit mention of supply chain disruptions in the transcript.

Competitive Pressures: Need to maintain and grow subscription-based revenue amidst competitive pressures in the market.

Debt Management: High debt levels with plans to retire secured notes by 2028, requiring consistent free cash flow generation to meet targets.

Operational Efficiency: Dependence on AI-enabled cost efficiencies to sustain margin expansion and cash flow growth, which may pose risks if implementation is delayed or ineffective.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Full Year Financial Guidance: Clarivate reaffirmed its full-year financial guidance for 2026, projecting organic annual contract value growth of 2%-3%, recurring organic revenue growth of about 1.5%, and adjusted EBITDA margin expansion to nearly 43%. Adjusted diluted EPS is expected to grow by about 9% to $0.75, and free cash flow is projected to grow by approximately 10% to $400 million.

Revenue and Profit Seasonality: Revenue is expected to remain stable in the next quarters, with a slight increase in Q4 due to seasonality. Profit margins are anticipated to expand throughout the year, driven by organic growth and the impact of disposals.

Debt Reduction Plan: Clarivate plans to use free cash flow to retire secured notes entirely by 2028 and begin retiring 2029 notes, aiming to reduce net leverage from 4x to approximately 2.5x in a few years.

Life Science & Healthcare Business Divestiture: The company is actively pursuing the sale of its Life Science & Healthcare business to concentrate on higher-return areas. Updates will be provided as the process progresses.

AI-Driven Efficiency and Innovation: Clarivate is embedding AI across various functions to drive efficiency, accelerate revenue growth, and support free cash flow acceleration. AI is being used in sales, customer care, software engineering, and corporate functions to automate workflows and improve scalability.

Subscription-Based Revenue Growth: The company is accelerating its shift to subscription-based offerings, with subscription organic revenue growth of 1.7% in Q1 and continued adoption of solutions like ProQuest.

Intellectual Property Segment Growth: The IP segment is showing improvement, with renewal rates up by 100 basis points and organic ACV trends nearing flat. New AI capabilities and contracts with national IP offices are expected to drive future growth.

Life Science & Healthcare Segment Growth: The shift from transactional sales to subscription is on track, with new customer wins for platforms like DRG Fusion and OFF-X. Strategic partnerships are expanding access to regulatory and scientific intelligence.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

Share Repurchase Program: During the first quarter, the company repurchased 7 million shares of stock to offset the dilutive impact of stock compensation vesting. Additionally, the company highlighted that the share repurchases completed last year contributed to an increase in adjusted diluted EPS by approximately $0.01.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you discuss the traction of your new AI products, customer reception, growth from these products, and the efficiency benefits from AI?

A:The company has been intensifying its investment in AI over the past 15-18 months. Internally, AI is being used for cost efficiencies in areas like go-to-market, customer support, sales operations, and corporate functions. Externally, AI innovation is focused on three waves: AI assistants, agentic AI, and ecosystem implementation. AI assistants have been implemented across various products, agentic AI has quadrupled throughput for some customers, and ecosystem implementation includes collaborations like the one with Anthropic. Financially, the company sees opportunities to expand margins and grow cash flows through AI efficiencies, with further details expected later this year.

Q:How do you view the competitive environment, especially with competitors also using AI?

A:The company feels confident about its position as an AI innovator, as recognized by Outsell. It has seen great adoption of its AI products across three segments: A&G, Life Sciences, and IP. Specific achievements include over 400 institutions using academic AI solutions, 10,000 researchers using Life Sciences AI products, and successful collaborations like the one with Anthropic. The company focuses on setting the scene rather than reacting to competitors.

Q:Can you provide an update on the China market and its opportunities?

A:China is a significant contributor to the company's A&G capabilities. The company sold 15 new Web of Science deals in China last year and sees strong momentum in A&G, Life Sciences, and IP. Specific developments include collaborations in Web of Science Research Intelligence. The company feels optimistic about its prospects in the Chinese market.

Q:What are your expectations for the IP segment, especially regarding growth and renewal cycles?

A:The company is the market leader in IP and offers a comprehensive range of products, including IPMS and intelligence products for trademarks and patents. Recent efforts include a new management team, improved sales execution, and strong AI innovation. The IP segment has shown steady progress, with slight improvements in renewal rates and organic ACV nearing flat after years of decline. The patent renewal business is expected to return to growth in the second half of this year, supported by improved market conditions and better sales execution.

Q:Why were transactional revenues down this quarter, and what would need to happen for A&G activity to rebound?

A:Transactional revenues were down due to lower A&G activity, primarily because of the timing of software implementations. The company expects transactional revenues to be slightly down for the full year, as anticipated. Improvements in the sales pipeline for software products could lead to better performance next year.

Q:What is driving growth in the A&G segment, and which subsegments are performing well?

A:The A&G segment has seen strong performance in research and analytics, led by the Web of Science product. Innovations like the Research Assistant and literature review agents have been well-received. The content business grows at or slightly below the segment average, while the software business has high renewal rates and new product innovations. Research and analytics are the primary drivers of growth.

Q:What is the current subscription mix in the Life Sciences & Healthcare segment, and how will this shift impact organic growth?

A:The Life Sciences & Healthcare segment has the highest proportion of transactional revenue but is progressing towards a subscription model. Product innovations and a focused commercial strategy are driving this shift. The company expects the recurring revenue mix to eventually reach the low 90s, with Life Sciences leading the way.

Q:Review of Unclear Management Responses

A:None of the questions were avoided or lacked clarity. All responses provided detailed and specific information.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

CLVT Transcript

Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

Positive4-29

Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript

Positive2-24

The company demonstrated strong financial performance with positive ACV growth, stable revenue retention, and improved EBITDA and cash flow. The Q&A highlighted optimism in AI product monetization and strategic synergies. Despite some unclear responses, the raised revenue guidance and focus on debt repayment over buybacks are seen as value-creating moves, suggesting a positive stock price movement.

Clarivate Plc (CLVT) Presents at Global Technology, Internet, Media & Telecommunications Conference 2025 Transcript

Neutral11-19

Clarivate Plc (CLVT) Q3 2025 Earnings Call Transcript

Unknown10-29

The earnings call presents a mixed outlook. Financial performance showed improvements in ACV and renewal rates, but revenue remained flat, and a net loss was reported. The Q&A highlighted innovation in AI and potential growth in IP, but management's unclear responses on long-term potential and AI's competitive edge raise concerns. Despite raised guidance, the flat revenue and net loss, coupled with market uncertainties, suggest a neutral sentiment. Given the mid-sized market cap, the stock is likely to see minor fluctuations, leading to a neutral prediction of -2% to 2%.

CLVT Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.

Explore More Earnings

Get Started

Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript